John Furey is the founder of Imvax. Imvax has raised $152M in total funding. Latest round: Series C. Based in Philadelphia, United States.
John P. Furey is the CEO of Imvax, a clinical-stage biotechnology company focused on personalized immunotherapies for brain cancer, a role he assumed in 2019. He previously held the position of COO at Spark Therapeutics. Under his leadership, Imvax secured significant funding rounds to advance its lead glioblastoma vaccine candidate.
Full founder directory · Investor directory · Company funding database · Fundraising library